Biogen (BIIB) risk factors: FY2025 10-K
Item 1A of the 10-K for the period ending 2025-12-31, filed 2026-02-06. 30 risk factor headings as filed. Read Item 1A in full · The whole 10-K · What changed since FY2024
1new since FY2024
7reworded
1removed
22unchanged
Headings mentioning a theme: Tariffs 0 · AI 1 · Cybersecurity 0 · China 0 · Interest rates 0. Compare across the S&P 500.
Risks Related to Our Business
8- We are substantially dependent on revenue from our products.
- Our long-term success depends upon the successful development of new products and additional indications for our existing products.
- If we fail to compete effectively, our business and market position would suffer.
- Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.
- Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.reworded
- We depend on relationships with collaborators and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control, and if these relationships fail, our business may be adversely affected.
- Our results of operations may be adversely affected by current and potential future healthcare reforms including those contained in the PPACA, IRA, OBBBA, MFN and executive orders.new
- Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful, our business may be adversely affected.reworded
Risks Related to Intellectual Property
1- If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed.
Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates
3- Successful preclinical work or early/late stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.reworded
- Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.
- Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.
Risks Related to Our Operations
9- A breakdown or breach of our information systems could subject us to liability or interrupt our business operations.reworded
- The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation.AI
- Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.
- Management, personnel and other organizational changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company, which could disrupt our business and adversely affect our operations.
- If we fail to comply with the extensive legal and regulatory requirements affecting the healthcare industry, we could face increased costs, penalties and a loss of business.
- Our sales and operations are subject to the risks of doing business internationally.
- We built a large-scale biologics manufacturing facility and are building a clinical packaging and other manufacturing facility, which represent a significant investment with no assurance that such investment will be recouped.reworded
- The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.
- The increasing use of social media platforms presents new risks and challenges.
Risks Related to Holding Our Common Stock
7- Our operating results are subject to significant fluctuations.
- Our investments in properties may not be fully realized.
- We may not be able to access the capital and credit markets on favorable terms, which could increase financing costs.reworded
- Our indebtedness could adversely affect us and limit our ability to plan for or respond to changes in our business.reworded
- Our investment portfolio is subject to market, interest and credit risk that may reduce its value.
- There can be no assurance that we will repurchase shares or that we will repurchase shares at favorable prices, which may negatively affect our stock price.
- Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.
General Risk Factors
2- Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts in our financial statements.
- Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury.
No longer in Item 1A
1Headings in the FY2024 10-K with no match this year.
- Our results of operations may be adversely affected by current and potential future healthcare reforms.
Headings are the lines of Item 1A set wholly in bold or italics, as the parser reads them, without the introductory paragraph that opens the section. A heading is new when no heading in the prior 10-K matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. Source: the filing on sec.gov.